Related Experiment Video
Updated: Jul 15, 2025
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
Recent advances on the role of monoamine oxidases in cardiac pathophysiology
Nina Kaludercic1,2, Ruth Jepchirchir Arusei3, Fabio Di Lisa4,5
1Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 58/B, 35131, Padua, Italy. nina.kaludercic@unipd.it.
Abstract:
Numerous physiological and pathological roles have been attributed to the formation of mitochondrial reactive oxygen species (ROS). However, the individual contribution of different mitochondrial processes independently of bioenergetics remains elusive and clinical treatments unavailable. A notable exception to this complexity is found in the case of monoamine oxidases (MAOs). Unlike other ROS-producing enzymes, especially within mitochondria, MAOs possess a distinct combination of defined molecular structure, substrate specificity, and clinically accessible inhibitors. Another significant aspect of MAO activity is the simultaneous generation of hydrogen peroxide alongside highly reactive aldehydes and ammonia. These three products synergistically impair mitochondrial function at various levels, ultimately jeopardizing cellular metabolic integrity and viability. This pathological condition arises from exacerbated MAO activity, observed in many cardiovascular diseases, thus justifying the exploration of MAO inhibitors as effective cardioprotective strategy. In this context, we not only summarize the deleterious roles of MAOs in cardiac pathologies and the positive effects resulting from genetic or pharmacological MAO inhibition, but also discuss recent findings that expand our understanding on the role of MAO in gene expression and cardiac development.
Insights
Monoamine oxidases (MAOs) produce harmful ROS in mitochondria, impairing heart function. MAO inhibitors offer a promising cardioprotective strategy by mitigating these effects.
Area of Science:
- Biochemistry
- Mitochondrial Physiology
- Cardiovascular Disease
Background:
- Mitochondrial reactive oxygen species (ROS) have complex roles, but their specific contributions independent of bioenergetics are unclear.
- Monoamine oxidases (MAOs) are unique mitochondrial enzymes producing ROS, hydrogen peroxide, aldehydes, and ammonia.
Purpose of the Study:
- To elucidate the detrimental impact of MAO activity on mitochondrial function and cellular viability.
- To explore the therapeutic potential of MAO inhibitors in cardiovascular pathologies.
- To review MAO's role in gene expression and cardiac development.
Main Methods:
- Review of existing literature on MAO function and its role in cardiovascular diseases.
- Analysis of the synergistic effects of MAO byproducts (ROS, aldehydes, ammonia) on mitochondrial integrity.
- Examination of studies on genetic and pharmacological MAO inhibition in cardiac models.
Main Results:
- Exacerbated MAO activity contributes to cardiovascular pathologies by impairing mitochondrial function.
- MAO byproducts synergistically damage cellular metabolic integrity and viability.
- MAO inhibition demonstrates cardioprotective effects, with potential roles in gene expression and cardiac development.
Conclusions:
- MAOs are significant contributors to mitochondrial dysfunction in cardiovascular disease.
- MAO inhibitors represent a viable therapeutic strategy for cardioprotection.
- Further research into MAO's broader roles in cardiac physiology is warranted.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:29Pathophysiology of Cardiac Performance
01:17Pathophysiology of Heart Failure
01:29Heart Failure II: Pathophysiology
01:29Cardiomyopathy V: Interprofessional Care
01:30Coronary Artery Disease I: Introduction